Expert Reviews Current State of CLL Treatment
Danielle Brander, MD, highlights how recent advances are changing the field of chronic lymphocytic leukemia and what it means for patients and their oncologists.
Regimen Shows Potential for Reducing TLS Risk in CLL
Kerry Rogers, MD, discusses the feasibility of a new treatment for tumor lysis syndrome and what research still needs to be done with these agents in chronic lymphocytic leukemia.
Umbralisib Shows Promise in Relapsed/Refractory CLL
Anthony R. Mato, MD, MSCE, discusses the next steps for umbralisib and the biggest challenges still facing patients with chronic lymphocytic leukemia.
Addressing the Unmet Needs for the Treatment of CLL
Susan M. O’Brien, MD, discusses the unmet needs in the treatment and management of patients with chronic lymphocytic leukemia.
Evaluating Pharmacologic Agents in Relapsed/Refractory CLL
Michael Choi, MD, elucidates essential indications and considerations for treating relapsed/refractory chronic lymphocytic leukemia (CLL) with approved pharmacologic agents.
Popular on OncLive
Key Characteristics Emerging for CAR T Cell Success
An effective lymphodepletion strategy is critical to success with chimeric antigen receptor T-cell therapy, but also the choice of patients and even the cells used for CAR T cell manufacturing should be made with care.